Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.87 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.87 |
| ▸ | CCR6 | P51684 | 2/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.69 |
| ▸ | GAA | P10253 | 4/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9849090 | 0.99 | KMT2A (0.98) | KMT2AMEN1MAPTALDH1A1TP53 | |
| SCHEMBL13702963 | 0.99 | KMT2A (0.98) | KMT2AMEN1MAPTALDH1A1TP53 | |
| Pirlindole SCHEMBL18878061 | 0.81 | HSD17B10 (1.00) | KMT2AMEN1MAPTALDH1A1TP53 | |
| Pirlindole SCHEMBL29500947 | 0.81 | HSD17B10 (1.00) | KMT2AMEN1MAPTALDH1A1TP53 | |
| Pirlindole SCHEMBL18877133 | 0.81 | HSD17B10 (1.00) | KMT2AMEN1MAPTALDH1A1TP53 | |
| Pirlindole SCHEMBL373564 | 0.81 | HSD17B10 (1.00) | KMT2AMEN1MAPTALDH1A1TP53 | |
| SCHEMBL12922443 | 0.81 | KMT2A (0.68) | KMT2AMEN1MAPTALDH1A1TP53 | |
| Pirlindole SCHEMBL4157397 | 0.81 | HSD17B10 (0.97) | KMT2AMEN1MAPTALDH1A1TP53 | |
| SCHEMBL12948590 | 0.81 | MEN1 (0.67) | KMT2AMEN1MAPTALDH1A1TP53 | |
| Pirlindole SCHEMBL1649683 | 0.80 | HSD17B10 (0.95) | KMT2AMEN1MAPTALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0457908-A1 | HYDROCHLORIDE 2,3,3a,4,5,6-HEXAHYDRO-8-CYCLOHEXYL-1H-PYRAZINO (3,2,1-j,k)CARBAZOL, METHOD OF OBTAINING IT AND A PHARMACEUTICAL PREPARATION OF ANTIDEPRESSIVE ACTION BASED ON IT | VSESOJUZNY NAUCHNO-ISSLEDOVATELSKY KHIMIKO-FARMATSEVTICHESKY INST. IMENI SERGO ORDZHONIKIDZE (VNIKHFI) (SU) | 1991-11-27 | — | — | EP | claimed |
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | NOVARTIS AG (CH) | 2019-11-19 | — | — | US | disclosed |
| US-10172854-B2 | Compositions and methods for treating mitochondrial diseases | BIOVISTA, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172854-B2 | Compositions and methods for treating mitochondrial diseases | BIOVISTA, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180110775-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | BIOVISTA INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110775-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | BIOVISTA INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110775-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | BIOVISTA INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180010132-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-7858560-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010068867-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068867-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2008150191-A1 | ANOREXIGENIC MEDICINAL AGENT FOR CONTROLLING THE BODY MASS | OTKRYTOE AKTSIONERNOE OBSCHESTVO 'OTECHESTVENNYE LEKARSTVA' (RU) | 2008-12-11 | — | — | WO | disclosed |
| EP-0457908-A1 | HYDROCHLORIDE 2,3,3a,4,5,6-HEXAHYDRO-8-CYCLOHEXYL-1H-PYRAZINO (3,2,1-j,k)CARBAZOL, METHOD OF OBTAINING IT AND A PHARMACEUTICAL PREPARATION OF ANTIDEPRESSIVE ACTION BASED ON IT | VSESOJUZNY NAUCHNO-ISSLEDOVATELSKY KHIMIKO-FARMATSEVTICHESKY INST. IMENI SERGO ORDZHONIKIDZE (VNIKHFI) (SU) | 1991-11-27 | — | — | EP | disclosed |
| EP-0457908-A1 | HYDROCHLORIDE 2,3,3a,4,5,6-HEXAHYDRO-8-CYCLOHEXYL-1H-PYRAZINO (3,2,1-j,k)CARBAZOL, METHOD OF OBTAINING IT AND A PHARMACEUTICAL PREPARATION OF ANTIDEPRESSIVE ACTION BASED ON IT | VSESOJUZNY NAUCHNO-ISSLEDOVATELSKY KHIMIKO-FARMATSEVTICHESKY INST. IMENI SERGO ORDZHONIKIDZE (VNIKHFI) (SU) | 1991-11-27 | — | — | EP | disclosed |
| WO-1991007968-A1 | HYDROCHLORIDE 2,3,3A,4,5,6-HEXAHYDRO-8-CYCLOHEXYL-1H-PYRAZINO (3,2,1-J,K)CARBAZOL, METHOD OF OBTAINING IT AND A PHARMACEUTICAL PREPARATION OF ANTIDEPRESSIVE ACTION BASED ON IT | VSESOJUZNY NAUCHNO-ISSLEDOVATELSKY KHIMIKO-FARMATSEVTICHESKY INSTITUT IMENI SERGO ORDZHONIKIDZE (VNIKHFI) (SU) | 1991-06-13 | — | — | WO | disclosed |
| WO-1991007968-A1 | HYDROCHLORIDE 2,3,3A,4,5,6-HEXAHYDRO-8-CYCLOHEXYL-1H-PYRAZINO (3,2,1-J,K)CARBAZOL, METHOD OF OBTAINING IT AND A PHARMACEUTICAL PREPARATION OF ANTIDEPRESSIVE ACTION BASED ON IT | VSESOJUZNY NAUCHNO-ISSLEDOVATELSKY KHIMIKO-FARMATSEVTICHESKY INSTITUT IMENI SERGO ORDZHONIKIDZE (VNIKHFI) (SU) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | PRMT5, PRMT1, PRMT3 | KMT2A 130/4885MEN1 249/4885MAPT 3050/4885 |
| US-10172854-B2 | Compositions and methods for treating mitochondrial diseases | MT-ND2, CS, UQCRC2 | KMT2A 3335/4885MEN1 3314/4885MAPT 762/4885 |
| US-20180110775-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | MT-ND2, CS, UQCRC2 | KMT2A 3335/4885MEN1 3314/4885MAPT 762/4885 |
| US-20180010132-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | PRMT5, PRMT1, PRMT6 | KMT2A 65/4885MEN1 198/4885MAPT 1870/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | KMT2A 4241/4885MEN1 2224/4885MAPT 2601/4885 |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | PRMT5, PRMT1, PRMT3 | KMT2A 130/4885MEN1 249/4885MAPT 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.